Changes in brain function during administration of venlafaxine or placebo to normal subjects

Clinical EEG and Neuroscience

Volumn 39, Issue 4, 2008, Pages 175-181

  Leuchter, Andrew F ^a,b   Cook, Ian A ^a,b   DeBrota, David J ^c   Hunter, Aimee M ^a,b   Potter, William Z ^d   McGrouther, Caroline C ^a,b   Morgan, Melinda L ^b   Abrams, Michelle ^a,b   Siegman, Barbara ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Lilly Research Laboratories

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cordance; Electroencephalography; Normal subjects; Placebo; Venlafaxine

Indexed keywords

DESVENLAFAXINE; DRUG METABOLITE; PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; ELECTROENCEPHALOGRAPHY; EYE MOVEMENT; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 57449099300     PISSN: 15500594     EISSN: None     Source Type: Journal    
DOI: 10.1177/155005940803900405     Document Type: Article

References (31)

1. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 2002; 12: 527-544.
2. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386: 824-827.
3. Drevets WC, Raichle ME. Neuroanatomical circuits in depression: implications for treatment mechanisms. Psychopharmacol Bull 1992; 28: 261-274.
4. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001; 58: 631-640.
5. Nobler MS, Sackeim HA, Louie J, Prohovnik I, Roose SF, Van Heertum R. Clinical response to antidepressants is associated with reduced frontal CBF in late-life depression. Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association; 1998: 168.
6. Nobler MS, Sackeim HA, Prohovnik I. Regional cerebral blood flow in mood disorders, III: treatment and clinical response. Arch Gen Psychiatry 1994; 51: 884-897.
7. Bares M, Brunovsky M, Kopecek M, Stopková P, Novák T, Kozeny J, et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. J Psychiatr Res 2007; 41: 319-325.
8. Cook IA, Leuchter AF, Morgan M, Witte E, Stubbeman WF, Abrams M, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 2002; 27: 120-131.
9. Cook IA, Leuchter AF. Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry 2001; 6: 113-120.
10. Bares M, Brunovsky M, Kopecek M, Novak T, Stopkova P, Kozeny J, et al. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur Psychiatr 2008 Apr 29.
11. Cook EH Jr, Metz J, Leventhal BL, Lebowitz M, Nathan M, Semerdjian SA, et al. Fluoxetine effects on cerebral glucose metabolism. NeuroReport 1994; 5: 1745-1748.
12. Smith GS, Ma Y, Dhawan V, Gunduz H, Carbon M, Kirshner M, et al. Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. Synapse 2002; 45: 105-112.
13. Saletu B, Grunberger J, Anderer F, Linzmayer L, Semlitsch HV, Magni G. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Br J Clin Pharmacol 1992; 33: 589-601.
14. Leuchter AF, Uijtdehaage SH, Cook IA, O'Hara R, Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res Neuroimaging 1999; 90: 125-140.
15. Cook I, Leuchter A, Morgan M, Stubbeman W, Siegman B, Abrams M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J Psychiatr Res 2005; 39: 461-466.
16. Leuchter AF, Cook IA, Uijtdehaage SH, Lufkin RB, Anderson-Hanley C, Abrams M, et al. Brain structure and function, and the outcomes of treatment for depression. J Clin Psychiatry 1997; 58 (suppl 16): 22-31.
17. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002; 159: 122-129.
18. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition. New York: Biometrics Research Department, New York State Psychiatric Institute; 1994.
19. Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry 2006; 163: 1426-1432.
20. Cook IA, O'Hara R, Uijtdehaage S, Mandelkern M, Leuchter AF. Assessing the accuracy of topographic EEG mapping for determining local brain function. Electroencephalogr Clin Neurophyiol 1998; 107: 404-414.
21. Cook IA, Leuchter AF, Witte E, Abrams M, Uijtdehaage S, Stubbeman W, et al. Neurophysiologic predictors of treatment response to fluoxetine in major depression. Psychiatry Res 1999; 85: 263-273.
22. Ulrich G, Haug HJ, Fahndrich E. Acute versus chronic EEG effects in maprotiline- and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome. J Affect Disord 1994; 32: 213-217.
23. Milligan GW, Cooper MC. Methodological review: clustering methods. Appl Psycholog Measurement 1987; 11: 329-354.
24. Mojena R. Hierarchical grouping methods and stopping rules: an evaluation. Computer Journal 1977; 20: 359-363.
25. Mirkin B. Mathematical Classification and Clustering. Dordrecht: Kluwer Academic Publishers; 1996.
26. Everitt B, Landau S, Leese M. Cluster Analysis. London: Oxford University Press; 2001.
27. Cook IA, Hunter AM, Abrams M, Siegman B, Leuchter AF. Midline and right frontal brain function as a biomarker of remission in major depression. Under review.
28. Leuchter AF, Cook IA, Hunter AM, Morgan ML, McGrouther CC, Abrams M. Functional changes in the brain associated with clinical response to duloxetine. Poster presented at European College of Neuropsychopharmacology. Stockholm, Sweden; 2004.
29. Roseboom PH, Kalin NH. Neuropharmacology of venlafaxine. Depress Anxiety 2000; 12: (Suppl 1): 20-29.
30. Hunter, AM, Leuchter, AF, Morgan, ML, et al. Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology 2005; 30: 792-799.
31. Ahmed S, Mozley PD, Potter WZ. Biomarkers in psychotropic drug development. Am J Geriatr Psychiatry 2002; 10: 678-686.